Management View - Curis, Inc. is making steady progress in its TakeAim Lymphoma study focused on primary CNS lymphoma, which is recognized as one of the rarest and most challenging types of lymphoma to treat [2] - The company aims to achieve full enrollment in the registrational study within 12 to 18 months [2] - Curis is also advancing its proof-of-concept study for chronic lymphocytic leukemia (CLL) [2]

Financial Data and Key Metrics Changes - ZYNLONTA net product revenues in Q4 2025 were $22.3 million, up from $16.4 million in Q4 2024, with full-year revenues at $73.6 million compared to $69.3 million in 2024 [21][22] - Total operating expenses were $41 million for Q4 2025 and $202.9 million for the full year, with adjusted operating expenses down 15% for Q4 and 6% for the full year compared to the previous year [21][22] - The net loss for Q4 2025 was $6.4 million, significantly reduced from a net loss of $30.7 million in Q4 2024, while the full-year net loss was $142.6 million compared to $157.8 million in 2024 [22][23] Business Line Data and Key Metrics Changes - The company focused on ZYNLONTA, optimizing lifecycle management and advancing clinical trials such as LOTIS-5 and LOTIS-7, which are expected to drive future growth [5][6] - The performance in Q4 was strong, driven by variability in customer ordering patterns and activation of new accounts, indicating a positive trend in sales [8] Market Data and Key Metrics Changes - The company anticipates a peak annual U.S. revenue opportunity for ZYNLONTA of $600 million to $1 billion, contingent on regulatory approval and compendia inclusion [7][11] - The treatment landscape for DLBCL is evolving, with a current 60/40 split between complex therapies and broadly accessible therapies, indicating a competitive market environment [15] Company Strategy and Development Direction - The strategic plan focuses on establishing ZYNLONTA as a backbone therapy in DLBCL, with significant patient benefits expected in indolent lymphomas [6][11] - The company aims to maintain a strong market position despite increased competition from bispecific therapies, leveraging its differentiated clinical profile [5][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving key milestones in 2026, including top-line data for LOTIS-5 and further data for LOTIS-7, which are critical for future growth [25][26] - The company believes it has laid a solid foundation for long-term growth, with a strengthened balance sheet and a cash runway extending into 2028 [10][24] Other Important Information - The company has made significant progress in reducing operating costs by approximately 50% while enhancing its leadership and talent across the organization [5][6] - An amendment to the royalty purchase agreement with HealthCare Royalty has provided greater strategic flexibility for the company [10] Q&A Session Summary Question: How are PFS events tracking for LOTIS-5? - Management is confident in the Q2 timing for the top-line readout and will share primary and secondary endpoints at that time [29][30] Question: Is the $200-$300 million opportunity for LOTIS-5 conservative? - Management believes the profile seen in the safety run-in supports a meaningful role in the second-line DLBCL market, with potential for higher peak sales depending on clinical outcomes [34][35] Question: What is the expected R&D spend moving forward? - R&D expenses are expected to decrease in 2026 and 2027, assuming the current number of trials remains stable [42][44] Question: How should capital allocation priorities be viewed? - The company is focused on driving ZYNLONTA growth and has allocated capital for ongoing trials and pre-launch activities, with strategic flexibility provided by the amended royalty agreement [48][50] Question: What is the current commercial run rate for ZYNLONTA? - The company has maintained its market share despite increased competition, with expectations for significant sales growth following LOTIS-5 approval [58][59]

Core Insights - Incyte (INCY) announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), indicating its potential as a first-line treatment option for newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients [1] Group 1: Drug Approval and Indications - Monjuvi, in combination with Bristol Myers' Revlimid (lenalidomide), is approved in the US and EU for adult patients with relapsed or refractory DLBCL [2] - The FDA has recently approved Monjuvi in combination with Revlimid and Roche's Rituxan (rituximab) for adult patients with relapsed or refractory follicular lymphoma (FL), expanding its application in hematologic malignancies [3] Group 2: Study Results and Efficacy - The pivotal phase III frontMIND study demonstrated that Monjuvi/Minjuvi combined with Revlimid and R-CHOP improved progression-free survival compared to R-CHOP alone, meeting its primary endpoint [4][6] - The study also achieved its key secondary endpoint of event-free survival, with no new safety signals reported, indicating a favorable safety profile [6][7] Group 3: Market Potential and Future Plans - Incyte plans to submit a supplemental biologics license application to the FDA for label expansion of Monjuvi for first-line DLBCL treatment in H1 2026, highlighting the company's commitment to addressing unmet medical needs [10] - DLBCL accounts for about 40% of non-Hodgkin lymphoma cases in adults, with approximately 24,000 new diagnoses annually in the US and up to 36,000 in the EU, underscoring the significant market potential for effective treatments [11]